Infections Clinical Trial
Official title:
Safety and Efficacy of Long-term Treatment With Echinaforce® Over 4 Months
Extracts produced from Echinacea purpurea are traditionally used for the prevention and the
acute treatment of influenzal infections like the common cold. The aim of this clinical
study is to assess clinical safety and efficacy of a treatment with Echinacea in comparison
to placebo. 750 healthy subjects with a history of equal or more than 2 cold episodes per
year will be recruited during October and November 2009 and will be treated with either
Echinacea or placebo over a period of 4 months.
Throughout the study period adverse events (AEs) and adverse drug reactions (AEs with at
least a possible causal relation to the treatment) will be recorded.
Common cold related symptoms will be recorded in a daily diary.
Status | Completed |
Enrollment | 757 |
Est. completion date | April 2011 |
Est. primary completion date | August 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - On average more than 2 cold episodes per year - Age above 18 years - Good physical condition - Signed informed consent Exclusion Criteria: - Women without appropriate and effective contraception - Participation in a clinical trial 30 days prior to this trial - Pregnant or breast feeding women - Subjects with pre-existing cold symptoms for more than 24h at inclusion - Concurrent participation in another clinical trial - Intake of antimicrobial and/or antiviral medications at inclusion - Alcohol and/or drug abuse, narcotic drug addiction before and during trial (more than 50 gr and / or 10 cigarettes per day) - Psychiatric disorders which may influence the results of the trial, - epilepsy, suicide attempts - Planned surgical intervention during the trial. - Serious chronic diseases which influence the absorption, metabolism and the elimination of the investigational product, especially progressive systemic illnesses like tuberculosis, leukaemia, - collagen disorders and multiple sclerosis - Known AIDS, HIV-infections and autoimmune diseases - Known diabetes mellitus (type 1) - Corticosteroid-treated asthma - Atopic and allergic subjects (under medicinal treatment) - Known allergy to plants of the composite family (Asteraceae) |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United Kingdom | Cardiff School of Biosciences | Cardiff | Wales |
Lead Sponsor | Collaborator |
---|---|
Bioforce AG |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence of Adverse Drug Reactions | 4 months | Yes | |
Secondary | efficacy | 4 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06055777 -
Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts
|
Phase 1 | |
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Recruiting |
NCT05793983 -
S100A8/A9 and Innate Immunity in Liver Disease
|
||
Active, not recruiting |
NCT05963269 -
The Effect of the Game on Students' Intramuscular Injection Skills
|
N/A | |
Not yet recruiting |
NCT02222779 -
Quantification of Transition Metals
|
N/A | |
Completed |
NCT01976234 -
Stored RBC Transfusion and Immonomodulation
|
N/A | |
Completed |
NCT01530763 -
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)
|
Phase 2/Phase 3 | |
Completed |
NCT02345135 -
Susceptibility to Infections in Ataxia Telangiectasia
|
N/A | |
Completed |
NCT01158560 -
A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections
|
Phase 3 | |
Completed |
NCT01176786 -
Reusable Versus Disposable Draping System in Breast Reconstruction Surgery
|
N/A | |
Active, not recruiting |
NCT05284097 -
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
|
Phase 2 | |
Enrolling by invitation |
NCT06055712 -
Antibiotic Prophylaxis in Pediatric Open Fractures
|
Phase 4 | |
Not yet recruiting |
NCT06402292 -
Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute
|
N/A | |
Not yet recruiting |
NCT06338345 -
Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients
|
N/A | |
Recruiting |
NCT06002685 -
Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention
|
N/A | |
Completed |
NCT02802059 -
E. Coli Nissle 1917 - Suspension for Infection Prophylaxis
|
Phase 3 | |
Completed |
NCT05289674 -
The Effect of Lactoferrin in High Calorie Formula on IL-6 and IL10 in Children With Failure to Thrive and Infection
|
N/A | |
Recruiting |
NCT05770765 -
Creation of a Bank of Biological Materials and Associated Data Related to Patients With Infectious and Tropical Diseases
|
||
Completed |
NCT05389540 -
Rural South and Southeast Asia Household Health Survey
|
||
Completed |
NCT05080920 -
Rosmalip® for Cancer Infections Prevention
|
N/A |